Introduction: Immunoadsorption (IA) represents a therapeutic option for acute antibody-mediated rejection (ABMR) after kidney transplantation. The addition of membrane filtration (MF) to enhance elimination of macromolecular components that potentially contribute to rejection, such as key complement component C1q and alloreactive IgM, may be an effective strategy to further improve its therapeutic efficiency. Results: Here we present 4 consecutive patients with episodes of HLA donor-specific antibody-positive ABMR nonresponsive to cycles of 6–16 sessions of IA treatment. Rejection episodes were characterized by severe microvascular injury (high-grade microcirculation inflammation and/or signs of thrombotic microangiopathy) and evidence of intense complement activation in peritubular capillaries (diffuse C4d-positivity). IA combined with MF led to substantial morphologic improvement (follow-up biopsies: g + ptc and C4d scores ≤1) and stabilization of allograft function. Conclusions: Our findings provide evidence for an effect of combination of IA + MF in refractory early acute/active ABMR in kidney transplant recipients.

Keywords:
Acute antibody-mediated rejection, Kidney transplantation, Immunoadsorption, Membrane filtration
1.
Amrouche L, Aubert O, Suberbielle C, Rabant M, Van Huyen JD, Martinez F, et al. Long-term Outcomes of Kidney Transplantation in Patients With High Levels of Preformed DSA: The Necker High-Risk Transplant Program.
Transplantation
. 2017 Oct;101(10):2440–8.
2.
Schwaiger E, Eskandary F, Kozakowski N, Bond G, Kikić Ž, Yoo D, et al. Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection.
Nephrol Dial Transplant
. 2016 Aug;31(8):1342–51.
3.
Böhmig GA, Eskandary F, Doberer K, Halloran PF. The therapeutic challenge of late antibody-mediated kidney allograft rejection.
Transpl Int
. 2019 Aug;32(8):775–88.
4.
Eskandary F, Bond G, Regele H, Kozakowski N, Kikic Z, Wahrmann M, et al. Late Antibody-Mediated Rejection in a Large Prospective Cross-Sectional Study of Kidney Allograft Recipients–Preliminary Results of the Screening Phase of the BORTEJECT Trial.
Clin Transpl
. 2014;23:189–95.
5.
Böhmig GA, Wahrmann M, Regele H, Exner M, Robl B, Derfler K, et al. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial.
Am J Transplant
. 2007 Jan;7(1):117–21.
6.
Lefaucheur C, Nochy D, Andrade J, Verine J, Gautreau C, Charron D, et al. Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection.
Am J Transplant
. 2009 May;9(5):1099–107.
7.
Locke JE, Magro CM, Singer AL, Segev DL, Haas M, Hillel AT, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection.
Am J Transplant
. 2009 Jan;9(1):231–5.
8.
Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection.
Am J Transplant
. 2004 Jun;4(6):996–1001.
9.
Stegall MD, Chedid MF, Cornell LD. The role of complement in antibody-mediated rejection in kidney transplantation.
Nat Rev Nephrol
. 2012 Nov;8(11):670–8.
10.
Burbach M, Suberbielle C, Brochériou I, Ridel C, Mesnard L, Dahan K, et al. Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts.
Transplantation
. 2014 Nov;98(10):1056–9.
11.
Everly MJ, Rebellato LM, Haisch CE, Briley KP, Bolin P, Kendrick WT, et al. Impact of IgM and IgG3 anti-HLA alloantibodies in primary renal allograft recipients.
Transplantation
. 2014 Mar;97(5):494–501.
12.
Bentall A, Tyan DB, Sequeira F, Everly MJ, Gandhi MJ, Cornell LD, et al. Antibody-mediated rejection despite inhibition of terminal complement.
Transpl Int
. 2014 Dec;27(12):1235–43.
13.
Orandi BJ, Zachary AA, Dagher NN, Bagnasco SM, Garonzik-Wang JM, Van Arendonk KJ, et al. Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation.
Transplantation
. 2014 Oct;98(8):857–63.
14.
Orandi BJ, Lonze BE, Jackson A, Terezakis S, Kraus ES, Alachkar N, et al. Splenic Irradiation for the Treatment of Severe Antibody-Mediated Rejection.
Am J Transplant
. 2016 Oct;16(10):3041–5.
15.
Eskandary F, Wahrmann M, Biesenbach P, Sandurkov C, König F, Schwaiger E, et al. ABO antibody and complement depletion by immunoadsorption combined with membrane filtration—a randomized, controlled, cross-over trial.
Nephrol Dial Transplant
. 2014 Mar;29(3):706–14.
16.
Defendi F, Malvezzi P, Eskandary F, Cesbron JY, Rostaing L, Böhmig GA, et al. Effects of immunoadsorption combined with membrane filtration on complement markers - results of a randomized, controlled, crossover study.
Transpl Int
. 2019 Aug;32(8):876–83.
17.
Biesenbach P, Eskandary F, Ay C, Wiegele M, Derfler K, Schaden E, et al. Effect of combined treatment with immunoadsorption and membrane filtration on plasma coagulation–results of a randomized controlled crossover study.
J Clin Apher
. 2016 Feb;31(1):29–37.
18.
Bartel G, Wahrmann M, Regele H, Kikić Z, Fischer G, Druml W, et al. Peritransplant immunoadsorption for positive crossmatch deceased donor kidney transplantation.
Am J Transplant
. 2010 Sep;10(9):2033–42.
19.
Orandi BJ, Montgomery RA, Segev DL. Kidney Transplants from HLA-Incompatible Live Donors and Survival.
N Engl J Med
. 2016 Jul;375(3):288–9.
20.
Bartel G, Schwaiger E, Böhmig GA. Prevention and treatment of alloantibody-mediated kidney transplant rejection.
Transpl Int
. 2011 Dec;24(12):1142–55.
21.
Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen JP, Mooney N, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival.
N Engl J Med
. 2013 Sep;369(13):1215–26.
22.
Guidicelli G, Guerville F, Lepreux S, Wiebe C, Thaunat O, Dubois V, et al. Non-Complement-Binding De Novo Donor-Specific Anti-HLA Antibodies and Kidney Allograft Survival.
J Am Soc Nephrol
. 2016 Feb;27(2):615–25.
23.
Viglietti D, Gosset C, Loupy A, Deville L, Verine J, Zeevi A, et al. C1 Inhibitor in Acute Antibody-Mediated Rejection Nonresponsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study.
Am J Transplant
. 2016 May;16(5):1596–603.
24.
Eskandary F, Wahrmann M, Mühlbacher J, Böhmig GA. Complement inhibition as potential new therapy for antibody-mediated rejection.
Transpl Int
. 2016 Apr;29(4):392–402.
25.
Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients.
Am J Transplant
. 2011 Nov;11(11):2405–13.
26.
Jordan SC, Lorant T, Choi J, Kjellman C, Winstedt L, Bengtsson M, et al. IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation.
N Engl J Med
. 2017 Aug;377(5):442–53.
27.
Everly MJ, Roberts M, Townsend R, Bray RA, Gebel HM. Comparison of de novo IgM and IgG anti-HLA DSAs between belatacept- and calcineurin-treated patients: an analysis of the BENEFIT and BENEFIT-EXT trial cohorts.
Am J Transplant
. 2018 Sep;18(9):2305–13.
28.
McMullen ME, Hart ML, Walsh MC, Buras J, Takahashi K, Stahl GL. Mannose-binding lectin binds IgM to activate the lectin complement pathway in vitro and in vivo.
Immunobiology
. 2006;211(10):759–66.
29.
Kuo HH, Fan R, Dvorina N, Chiesa-Vottero A, Baldwin WM 3rd. Platelets in early antibody-mediated rejection of renal transplants.
J Am Soc Nephrol
. 2015 Apr;26(4):855–63.
© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.